Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study

Autor: Espinosa, E, Soriano, V, Malvehy, J, Berrocal, A, de Prado, PM, Quindos, M, Soria, A, Marquez-Rodas, I, Palacio, I, Cerezuela, P, Lopez-Vivanco, G, Alonso, L, Samaniego, E, Ballesteros, A, Puertolas, T, Diaz-Beveridge, R, de la Cruz-Merino, L, Castro, RL, Lopez, RL, Stevinson, K, del Barrio, P, Tornamira, MV, Guillem, V, Martin-Algarra, S

Publikováno v: MELANOMA RESEARCH
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Adjuvant interferon-alpha 2b (IFN-alpha 2b) has been studied extensively in clinical trials, but there have been few studies of real-world use. The aim of this study is to describe the IFN-alpha 2b real-world patterns in patients with high-risk melan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bdcac216fd7b183239f44929f324f336
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9153

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Autor: Espinosa E; aMedical Oncology Service, Hospital Universitario La Paz bMedical Oncology Service, Hospital Ramón y Cajal cMedical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañon dMedical Oncology Service, Hospital La Princesa eMedical Affairs, Merck Sharp & Dohme, Madrid fMedical Oncology Service, Instituto Valenciano de Oncología gMedical Oncology Service, Hospital General Universitario de Valencia hMedical Oncology Service, Hospital La Fe, Valencia iMedical Oncology Service, Hospital Clinic de Barcelona, Barcelona jMedical Oncology Service, Hospital de Basurto, Bilbao kMedical Oncology Service, Hospital Teresa Herrera, La Coruña lMedical Oncology Service, Hospital Central de Asturias, Oviedo mMedical Oncology Service, Hospital General Universitario Santa Lucía, Cartagena nMedical Oncology Service, Hospital de Cruces, San Vicente de Baracaldo oMedical Oncology Service, Hospital Universitario Virgen de la Victoria, Málaga pDermatology Service, Complejo Asistencial Universitario de León, León qMedical Oncology Service, Hospital Miguel Servet, Zaragoza rMedical Oncology Service, Hospital Virgen de la Macarena, Sevilla sMedical Oncology Service, Hospital Clínico Universitario de Valladolid, Valladolid tMedical Oncology Service, Hospital Clínico Universitario de Santiago, Santiago de Compostela uMedical Oncology Service, Clínica Universitaria de Navarra, Pamplona, Spain vGlobal Health Outcomes Research, Merck Sharp & Dohme, Kenilworth, New Jersey, USA., Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S

Publikováno v: Melanoma research [Melanoma Res] 2016 Jun; Vol. 26 (3), pp. 278-83.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

Autor: Escobar Y; Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, 28007, Madrid, Spain., Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, Tamés MJ, Muros B, Lecumberri MJ, Feliu J, Martínez P, Adansa JC, Martínez MJ, López R, Blasco A, Gascón P, Calvo V, Luna P, Montalar J, Del Barrio P, Tornamira MV

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2015 Sep; Vol. 23 (9), pp. 2841.

Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

Autor: Tsuchihashi K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan., Ito M; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan., Okumura Y; Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan., Nio K; Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan., Ozaki Y; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Nishio H; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan., Ichihara E; Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan., Miura Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan., Endo M; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan., Yano S; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Maruyama D; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Yoshinami T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan., Susumu N; Department of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan., Takekuma M; Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan., Motohashi T; Department of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan., Ochi N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Kubo T; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan., Uchino K; Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan., Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Kamiyama Y; Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan., Nakao S; Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan., Tamura S; Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan., Nishimoto H; Department of Nursing, Okayama University Hospital, Okayama, Japan., Kato Y; Department of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan., Sato A; Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan., Takano T; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. baba.eishi.889@m.kyushu-u.ac.jp.

Publikováno v: International journal of clinical oncology [Int J Clin Oncol] 2024 Jun; Vol. 29 (6), pp. 700-705. Date of Electronic Publication: 2024 May 02.